Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Syros Pharmaceuticals
< Previous
1
2
Next >
Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update
July 31, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
July 24, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
June 13, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
May 14, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros to Participate in Upcoming Investor Conferences
May 07, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
May 07, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
April 09, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
March 27, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
March 25, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
March 20, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros to Participate in TD Cowen 44th Annual Health Care Conference
February 27, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene
January 08, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
December 19, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
December 06, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros to Participate in Upcoming Investor Conferences
November 21, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
November 14, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
November 07, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company
October 02, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 07, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
August 08, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
August 01, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros to Present at Sidoti June 2023 Virtual Small-Cap Conference
June 08, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting
May 25, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update
May 10, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros to Present at JMP Securities 2023 Life Sciences Conference
May 09, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
May 03, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit